Akeso (HKG:9926) widened its attributable loss for the year 2025 to 1.11 billion yuan from 514.5 million yuan a year prior, according to a Thursday Hong Kong bourse filing.
Shares of the drug company were up nearly 3% in Friday afternoon trading.
Loss per share stood at 1.23 yuan in the fiscal year, compared with 0.60 yuan in the previous corresponding year.
Revenue jumped 44% to 3.06 billion yuan in the period from 2.12 billion yuan in the year-ago period, supported by the initial inclusion of cadonilimab and ivonescimab into the China National Reimbursement Drug List.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments